Attorney Docket No.: UM-07269



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Gary D. Glick

Serial No.:

09/767,283

Filed:

01/22/2001

Group No.:

1618

Examiner:

Kim, Vickie Y.

Entitled:

Therapeutic Application of Pro-Apoptotic Benzodiazepines

TRANSMITTAL

Mail Stop Amendments

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

CERTIFICATE OF MAILING UNDER 37 CFR § 1.8(a)(1)(i)(A)

I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is, on the date shown below, being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendments, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Sir or Madam:

Enclosed please find a Supplemental Information Disclosure Statement and Form PTO-1449, in the above-identified application, for filing in the U.S. Patent Office.

Applicants believe no fee is required. The Commissioner is hereby authorized to charge any additional fee or credit overpayment to our Deposit Account No. 08-1290. An originally executed duplicate of this transmittal is enclosed for this purpose.

Dated: November 29, 2006

Robert A/Goetz Registration No. 55,210

MEDLEN & CARROLL, LLP 101 Howard Street, Suite 305 San Francisco, California 94105

608/218-6900



E UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Gary D. Glick

Serial No.:

09/767,283

09/707,203

Group No.:

1618

Filed:

01/22/2001

Examiner:

Kim, Vickie Y.

Entitled:

Therapeutic Application of Pro-Apoptotic Benzodiazepines

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendments Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

CERTIFICATE OF MAILING UNDER 37 CFR § 1.8(a)(1)(i)(A)

I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is, on the date shown below, being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendments, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: November 29, 2006

By:

lennifer B. Xistris

Sir or Madam:

The citations listed below may be material to the examination of the above-identified application, and are therefore submitted in compliance with the duty of disclosure defined in 37 C.F.R. §§ 1.56 and 1.97. The Examiner is requested to make these citations of official record in this application.

- US Patent Number 6,277,844 B1 issued on 08/21/2001 to Spector, et al
- G.B. Jones, et al., The Non-covalent Interaction of pyrrolo [2, 1-c] [1,4] benzodiazepine-5, 11-diones with DNA, Anti-Cancer Drug Design, 5:249-264 (1990)
- International Search Report from WO 03/015703 A3 Published on February 27, 2003.
- International Search Report from WO 2005/004988 A3 Published on January 20, 2005
- International Search Report from WO 00/66106 A3 Published on November 11, 2000

This Information Disclosure Statement under 37 C.F.R. §§ 1.56 and 1.97 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one or more of these extations constitutes prior art.

Dated: November 29, 2006

Registration No. 55,210

MEDLEN & CARROLL, LLP 101 Howard Street, Suite 350 San Francisco, California 94105

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Complete if Known

09/767,283

01/22/2001

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE under the research Reduction of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Number

Filing Date

Substitute for form Page 10

Sheet 1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

First Named Inventor	Gary Glick
Art Unit	1618
Examiner Name	Kim. Vickie Y.

Attorney Docket Number UM-07269

			U. S. PATEN	DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	^{US-} 6,277,844	08/21/2001	Spector, et al	Whole Document
		US-			
	-	US-			
		US-	*		
		US-			
	<u> </u>	US-		· · · · · · · · · · · · · · · · · · ·	
		US-	1		
		US-			
		US-	+		

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ^{3 -} Number ^{4 -} Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T ⁶
	2	WO 03/015703 A3	02/27/2003	Glick, Gary D.	Whole Document	
	3	WO 2005/004988 A	01/20/2005	Glick, Gary D.	Whole Document	
	4	WO 00/66106 A3	11/09/2000	Glick, Gary D.	Whole Document	L
	ļ					

Examiner		Date	
Signature		Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known		
Application Number	09/767,283	
Filing Date	11/08/2001	
First Named Inventor	Gary D. Glick	
Art Unit	1618	
Examiner Name	Kim, Vickie Y.	
Attorney Docket Number	UM-07269	
	Filing Date First Named Inventor Art Unit Examiner Name	

,			
		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	5	Jones, "The non-conalent interaction of pyrrolo[2, 1-c][benzodiazepines-5, 11-diones with DNA, Anti-Cancer Drug Design, 5:249-264 (1990)	
	·		
Examiner	1	Date	
	1	I Date I	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.